Rilzabrutinib authorised to treat adults with immune thrombocytopenia when prior treatments have been insufficient
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (29 May 2026) granted a marketing authorisation for the medicines rilzabrutinib…